News Archive

Biomarker predictive of death after heart failure

The group of Prof. Bischoff (BDC site Groningen) recently contributed to the discovery and validation of a metabolite biomarker that has predictive value for death after heart failure. The collaboration with Prof. van der Meer (University Medical Center Groningen) showed that the enzyme 5-oxoprolinase has a protective effect and that elevated plasma levels of 5-oxoproline are associated with a worse clinical outcome. The results of this study were published in Science Translational Medicine. View Pubmed record here. (Posted on 12 December 2017)

FABIAN Symposium, Groningen

Fabian conference attendees

The 2017 edition of the FABIAN symposium of the Bioanalysis Working Group of the Royal Dutch Chemical Society (KNCV) in close collaboration with the Belgian Bioanalysis Working Group brought together young scientists and experts in bioanalysis during an inspiring day at the ERIBA Institute of the University of Groningen. About 70 participants discussed new possibilities of using high-resolution mass spectrometry in (regulated) bioanalysis.
After an overview given by one of the pioneers of modern mass spectrometry, Prof. Hopfgartner from the University of Geneva (Switzerland), there were presentations related to scientists and practitioners from industry and international research institutes. The afternoon session went into specific examples of therapeutic protein analysis, ultra-high resolution mass spectrometry and proteomics.
The symposium allowed renewing acquaintances and making new contacts. We are looking forward to an equally successful symposium in 2018 to bring the Dutch and Belgian bioanalysis community together again. (Posted on 18 October 2017)

MSACL Lecture, Salzburg

Prof. Rainer Bischoff of the BDC gave a plenary lecture at the MSACL symposium on Mass Spectrometry in the Clinical Laboratory in Salzburg, Austria. The slides can be found here. (Posted on 22 September 2017)

Waters MS Technology Days 2017: Evaluation of biomarkers predictive for Alzheimer's disease

During the Waters MS Technology Days 2017 in Basel (6/27) and Lausanne (6/27) research results were presented from a BDC study carried out in the group of Dr. Theo Luider at the Erasmus MC (Rotterdam) about development and application of an LC-MS assay to evaluate Pregnancy Zone Protein as potential biomarker for the prediction of Alzheimer's disease. Information about the meeting here. (Posted on 24 August 2017)

Fabian meeting: Applications of High Resolution Mass Spectrometry

This year's Fabian meeting will be organized on Wednesday October 11th at the campus of Groningen University, ERIBA building, Antonius Deusinglaan 1, 9713 AV Groningen, and will focus on Applications of High Resolution Mass Spectrometry. The pre-final program can be viewed here. (Posted on 18 July 2017)


Webinar: Proteoforms: A Matter of Preservation in Proteomics

Learn more about the importance of proteoforms from both fundamental and clinical research perspectives and the potential of top-down proteomics using real-life examples. Furthermore the webinar will help you implement top-down proteomics.
Speaker: Hans Wessels, Proteomics Scientist, Radboud University, Nijmegen, Department of Laboratory Medicine.
The webinar was presented on 07 June 2017. Full information here. (Posted 08 June 2017)


EATRIS Conference, Prague, September 24-26, 2017

EATRIS, the European Infrastructure for Translational Medicine in which the BDC laboratories of profs Bischoff, Luider and van Gool are members, will hold its annual Translational Conference in Prague, September 24-26. Conference information here. (Posted 17 May 2017)


Webinar: Quantification of proteins in complex biological samples by LC-MS/MS

This 30 minute webinar, presented by Prof. Rainer Bischoff of the BDC, tells about

  • How to set up a targeted LC-MS/MS method for a given protein
  • How different approaches to sample preparation and internal standards affect sensitivity
  • How LC-MS/MS assays can be multiplexed

The webinar was presented on 25 May 2017 at 15:00 British Summer Time.
Register and view the webinar here. (Posted 11 May 2017 and updated on 31 May 2017)


MALDI-TOF mass spectrometry for quantitative biomarker analysis

MALDImmunoassays are not widely used in clinical diagnostics, which is mainly due to the limited availability of internal standards that can adequately correct for variability in sample preparation and the MALDI process itself. Here researchers from the BDC present a novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma. See the paper here. (Posted 11 May 2017)


Bridging the translational innovation gap through good biomarker practice

In collaboration with the European technology infrastructures EATRIS, BBMRI and ELIXIR, prof van Gool and other scientists from the Biomarker Development Center published a comment in Nature Reviews Drug Discovery to join efforts in defining the Good Biomarker Principle guidelines that will support successful biomarker discovery and development activities. These guidelines will be defined in the COST action CliniMARK, initiated and coordinated by dr Luider of the BDC. See comment here. (Posted 10 May 2017)


Proteomics Forum 2017

At the recent Proteomics Forum 2017 in Potsdam, Germany, Prof. Alain van Gool outlined the translational biomarker activities at the BDC unit at the Radboudumc, outlining workflows where proteomics, glycomics and metabolomics complemented the genomics-based diagnostic sequencing of patients. View presentation here. (Posted 15 April 2017)


Conference announcement: the HUPO 2017

This conference will take place in Dublin September 17-21, 2017. Conference information is available here. Prof. Alain van Gool will give a keynote lecture on "Integrated 'omics and their role in personalized healthcare now and in the future" (see here). (Posted 15 April 2017)


CliniMARK Kick-off meeting

The CliniMARK network has the goal of establishing "Best Biomarker Practice" (BBP) guidelines to radically improve the process from biomarker discovery to clinical use. The kick-off meeting was held at the COST offices in Brussels on March 14, 2017. A plan was developed to define BBP guidelines and to apply these guidelines for the validation of biomarkers with COPD as an example. The next meeting will be held from October 5 to 7, 2017, at the Erasmus MC (Rotterdam) in conjunction with the Biomarker Symposium. For further information please contact t.luider@erasmusmc.nl. (Posted 20 March 2017)


12th Biomarker Congress

Prof Alain van Gool recently lectured at the 12th Biomarker Congress in Manchester organized by Oxford Global, outlining various technological infrastructures that aim to close the biomarker innovation gap, including the Biomarker Development Center, DTL, EATRIS and Health-RI. The presentation can be viewed here. (Posted 25 February 2017)


Agilent Seminar Tour. Metabolomics and Beyond: Solutions for Understanding Metabolomics, 15 February 2017, Nijmegen

Gain insights on the newest techniques and comprehensive solutions for Metabolomics. Meet with your peers and Agilent specialists and discuss latest research advances and best practices on analytical methods and software workflows. Participation is free and the number of participants is limited. Information and registration here. (Posted 28 January 2017)


Keynote lecture IHE congress

Prof. van Gool of the BDC will give a keynote lecture at the annual IHE congress (Nov. 11). The interview with Prof. van Gool prior to this congress can be found here (in Dutch). (Posted 06 November 2016)


COST action on good biomarker practice

Biomarker Development Center (BDC) leads new COST action 'CliniMARK' on good biomarker practice to increase the number of clinically validated biomarkers (COST Action number: CA16113) funded by the European Commission. This network comprises members from 16 countries including Canada and the USA. (Posted 06 November 2016)


Early Detection of Lung Cancer

The thesis of Ingrid Broodman (Erasmus MC, Rotterdam) entitled "Early Detection of Lung Cancer - A role for serum biomarkers?" describes how sequencing the variable, complementarity-determining regions of autoantibodies may open new avenues to specific biomarkers that can discriminate between malignant nodules in patients suspected of lung cancer from benign nodules. This is a new and exciting area of personalized medicine requiring cutting-edge analytical approaches based on liquid chromatography combined with high-resolution mass spectrometry, as available in the Biomarker Development Center. The thesis can be found here. (Posted 12 October 2016)


Personalized Healthcare Lecture

Prof. Dr. Alain van Gool from the RadboudUMC spoke at a special event about personalized healthcare and the role of technologies in achieving its goals. The lecture can be watched here and the slides of the lecture can be consulted here. This link gives also access to slides that Prof. van Gool showed at the recent Copenhagen Bioscience Lecture. (Posted 12 October 2016)


Europe Biobanking Week

The recent Europe Biobanking Week in Vienna focused on the use of biospecimens and was organized by BBMRI and ESBB (see website). Eight hundred participants followed Prof. van Gool's lecture about the necessity of improving the quality and not the quantity of biomarker candidates and developing them into valid, clinically relevant assays. The slides of the lecture can be consulted here. (Posted 12 October 2016)


German Society of Laboratory Medicine

During the recent meeting of the German Society of Laboratory Medicine in Mannheim, Prof. Dr. Rainer Bischoff presented his view on the principle differences between ligand binding assays and LC-MS based bioanalytical approaches. The slides of his lecture can be found here. (Posted 12 October 2016)


European Infrastructure for Translational Medicine

Members of the BDC recently joined the European Infrastructure for Translational Medicine (EATRIS) as part of the Biomarkers Product Platform. This EU-wide network of infrastructures will allow the BDC to collaborate with other organizations in this area and attract interested parties that would like to validate biomarker candidates. EATRIS will help open doors in the direction of larger EU projects, for example as part of the IMI initiative. (Posted 25 August 2016)


Glossary of Biomarkers and related tools

The National Institutes of Health biomarker initiative recently published a glossary on Biomarkers, EndpointS, and other Tools (BEST), which may be of interest to researchers in the field. (Posted 25 August 2016)


Large-Scale Infrastructure

The Biomarker Development Center (BDC) forms part of the Large-Scale Infrastructure plans of the Dutch Government to promote translational and personalized health care. We expect a call to be launched in early 2017 to provide funding for Large-Scale Infrastructures in the Netherlands. More info here. (Posted 13 July 2016)


Personalized medicine

Personalized medicine is more than just matching the treatment to the individual genetic background of the patient. In an interview in Medisch Contact, a Dutch journal for clinicians, Alain van Gool reflects on approaches towards successful implementation of personalized medicine using molecular biomarkers, and the challenges and opportunities that lie ahead. Full article [in Dutch] here. (Posted 08 July 2016)


Skyline User Group Meeting 2016

On June 5 2016, the day before the start of the ASMS conference, BDC-researcher Diana Nijholt will give an oral presentation at the Skyline User Group Meeting in San Antonio (Texas) on validation of PZP as a biomarker for presymptomatic Alzheimer’s disease. More news here. (Posted 01 May 2016)


Measurement of desmosine and isodesomosine in urine of COPD patients

The Bischoff lab recently published a paper on the importance of confounding factors for the measurement of desmosine and isodesmosine in urine of COPD patients. Desmosine and isodesmosine levels in urine have long been claimed to predict lung function decline due to emphysema development. However, this large-scale study with samples from the ECLIPSE study shows that confounding factors like age, BMI etc. overrule the differences in desmosine and isodesmosine to an extent that their levels cannot be used to predict lung function decline or response to therapy in COPD. Read the article here. (Posted 03 April 2016)


Review on biomarkers for COPD

The Bischoff group recently published a review article summarizing their strategy to prioritize biomarkers for COPD based on an extensive search through the literature and various databases with clearly defined criteria. This is the first step of every BDC biomarker validation project. The review was published upon invitation in the first issue of the newly launched journal Advances in Precision Medicine of which Rainer Bischoff is member of the editorial board. Article here. (Posted 03 April 2016)


Internist Cees Tack reflects on diabetes and the role of the BDC in internal medicine

There is a rapidly increasing global prevalence of obesity, which originates from chronic overnutrition and physical inactivity. Obesity can lead to metabolic disturbances, such as dyslipidemia, hypertension, hyperglycemia and insulin resistance, the underlying cause of Type 2 Diabetes (T2D).
Read the full article. (Posted 25 January 2016)


Launch of new journal: Advances in Precision Medicine

Khusru Asadullah from the Scientific Advisory Board of the BDC has accepted the position of Editor in Chief of the newly launched journal Advances in Precision Medicine (APM). Alain van Gool and Rainer Bischoff, both of the BDC, accepted to join the Editorial Advisory Board of APM. We do hope and expect this new journal to thrive in a very exciting area that is of major interest to the BDC. (Posted 19 January 2016)


Survivin autoantibodies are not elevated in lung cancer

The high mortality rate in lung cancer is largely attributable to late diagnosis. Case-control studies suggested that autoantibodies to the survivin protein could serve as potential biomarkers for early diagnosis. However, this study showed that specific anti-survivin autoantibody reactivity is most likely not present in sera before or after diagnosis. See I Broodman et al. in the recent Cancer Immunology Research. (Posted 01 January 2016)


Biomarker Development Center (BDC) in the news

As one of the highlighted public-private partnerships in biomarker development, the BDC has recently been named in Nature Reviews in Drug Discovery as an example of collaboration between industry and academia. The BDC maintains its commitment to bringing validated biomarkers to the clinic in a joint effort with industry and major stakeholders such as patient organizations. See Asadullah K, Busch A, Gottwald M, Reinke P, Landeck L. Industry-academia collaborations for biomarkers. Nat Rev Drug Discov, 14(12), 805-806 (2015). (Posted 06 December 2015)


Antibodies in Biomarker Research

Three teams of the BDC work on different aspects of antibody-related questions in biopharmaceutical and biomarker research. The groups of Luider (Erasmus Medical Center, Rotterdam) and Wevers (Radboud University Medical Center, Nijmegen) focus on the question whether the concentration of free light chains in serum can give an indication of diseases all related to the uncontrolled expansion of antibody-producing cells (e.g. symptomatic myeloma). VanDuijn MM et al. Anal Chem, 87, 8268-8274 (2015). Another aspect of the immune reaction is that pharmaceutical proteins may be neutralized by anti-drug antibodies. The group of Bischoff (University of Groningen) has looked into this aspect in collaboration with PRA Health Sciences (Assen, the Netherlands) and the Pompe Center (Erasmus Medical Center, Rotterdam) to evaluate anti-glucosidase antibody formation in Pompe Disease patients. Bronsema KJ et al. Anal Chem, 87,4394-4401 (2015).


Biomarkers in Personalized Healthcare

Two recent interviews with Alain van Gool, professor of personalized healthcare, have appeared in the press. These articles have raised interest over potential clinical applications among the medical profession and the public. Dokter DNA [in Dutch] and Wereldtoppers [in Dutch]. (Posted 01 October 2015)


Horizon 2020 Recognizes Need for Standardization

The European Union recognizes that a lack of standardization of pre-analytical and analytical procedures is one of the bottlenecks in bringing new in vitro diagnostic tests to the market and to the patient. The Horizon 2020 program has therefore launched a call for projects on the topic "Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine." Members of the Biomarker Development Center (BDC) have been at the forefront of investigating the effect of pre-analytical parameters on the outcome of proteomics and metabolomics studies and will continue to do so. Sample publications include the following: Rosenling T et al. Clinical Chemistry, 57(12), 1703-1711 (2011); Rosenling T et al. J Proteome Res., 8, 5511-5522 (2009); and Govorukhina NI et al. J. Chromatogr. B, 877, 1281-1291 (2009).


FDA Approves First COPD Biomarker

The COPD Foundation is extremely pleased to announce that a new clinical biomarker, plasma fibrinogen, has been approved for use in interventional clinical trials in patients with chronic obstructive pulmonary disease, the 3rd leading cause of death in the USA. This is the first COPD biomarker to receive qualification by the U.S. Food and Drug Administration (FDA) and is the result of six years of work by the COPD Biomarker Qualification Consortium (CBQC). More (Posted 19 August 2015)


Biomarkers Pancreatic Ductal Adenocarcinoma

Biomarker panels, as reported in an earlier news item by Boichenko et al. for squamous cell cervical carcinoma, are coming of age. A recent paper led by a group of researchers from Queen Mary University of London shows that a panel of 3 proteins measured in urine greatly improves the early detection of pancreatic ductal adenocarcinoma (PDAC). It is expected that the non-invasive analysis of this protein panel will improve survival from this highly invasive type of tumor. Article (Posted 06 August 2015)

Bridging the Biomarker Gap

Rainer Bischoff of the University of Groningen, comments in the Analytical Scientist that "biomarker discovery and validation relies heavily on reproducible and robust analytical methodology. Separation science and notably high performance liquid chromatography (HPLC) are essential and efforts spent in developing more efficient and robust HPLC stationary phases, together with advanced mass spectrometers, have made modern biomarker research possible." Article (Posted 22 June 2015)


Pulmonologist Nick ten Hacken reflects on COPD

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the world and represents an important public health challenge that is both preventable and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world: many people suffer from this disease for years and die prematurely from its complications. Feature article (Posted 14 June 2015)


Singulex Announces EMD Millipore to Acquire Exclusive Rights to Singulex’s Ultra-Sensitive Single Molecule Counting (SMCTM) Technology

Singulex, Inc., the developer and leading provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery, today announced today that they have entered into a definitive agreement under which EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, will control and manage the Singulex Life Science Research business, one of Singulex’s three areas of business. Read more. (Posted 21 May 2015)


BDC Program Meeting

The Biomarker Development Center (BDC) held its first full program meeting on March 16, 2015 at the Erasmus Medical Center in Rotterdam. All projects were discussed with a focus on the in silico prioritization of biomarkers for validation in the 3 disease areas Diabetes Type-II, COPD and Alzheimer. Prioritization will be finalized with advice from the stakeholders on April 23, 2015 at our first meeting at TNO in Zeist. (Posted 12 April 2015)


Avacta Life Sciences

We are happy to announce that Avacta Life Sciences joins the group of industry supporters. Avacta's expertise in affimers as affinity ligands will be of great value to move some of the selected biomarker candidates forward towards validation. (Posted 12 April 2015)


10th Biomarker Congress in Manchester

Prof Alain van Gool recently lectured at the 10th Biomarker Congress in Manchester organized by Oxford Global, outlining how biomarkers in personalized healthcare are enabling innovations beyond just targeted medicines. (Posted 12 April 2015)


EATRIS Finland

At the recent opening of EATRIS Finland in Helsinki, Prof Alain van Gool gave a keynote lecture describing how the integrated technological infrastructure at the Radboudumc supports personalized healthcare applications and how the innovation gap in biomarker validation can best be addressed through open innovation networks. (Posted 12 April 2015)


Workshop Translational Research

BDC partner Waters will hold a workshop on Translational Research at the Radboud University Medical Center in Nijmegen on April 22. Speakers from the BDC and Waters will give their views on where this area is going with examples from areas of Biomarker Research and the Bioanalysis of Biopharmaceuticals. The workshop will further highlight innovations in analytical technology and bioinformatics. (Posted 2 Apr 2015)


Opening Dutch Biomarker Development Center

The Dutch Biomarker Development Center held its kick-off meeting on November 20, 2014 at the University of Groningen (see photos and film). The Center is a public-private initiative to advance biomarker candidates from discovery to the clinic based on the development of novel technologies and a close collaboration with leading clinical research groups. For more information contact Dr. Rainer Bischoff. (20 Nov 2014)


Biomarker Panel for Cervical Cancer

It is likely that single biomarkers will not be the answer to the diagnosis of complex, multi-factorial diseases. Dr. Bischoff's group recently published results about a panel of 6 serum proteins that outperform current clinical tests in predicting cervical intraepithelial neoplasia, a precancerous stage of cervical cancer. Read more here. (18 Sep 2014)


STW Grant

The BDC has received a 4.3 million euro grant from the Dutch Technology Foundation (STW) to develop high-throughput, high-sensitivity technology for biomarker development in close collaboration with a number of industrial partners. Read more here. (3 Dec 2013)




RUG UMCG EMC RUMC TNO